Results 51 to 60 of about 112,964 (206)
The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells.
PLoS ONE, 2013 Resistance to cisplatin-based therapy is a major cause of treatment failure in human ovarian cancer. A better understanding of the mechanisms of cisplatin resistance will offer new insights for novel therapeutic strategies for this deadly disease.
Akechai Im-aram +6 more
doaj +1 more source
MTMR6 downregulation contributes to cisplatin resistance in oral squamous cell carcinoma
Cancer Cell InternationalBackground The therapeutic effectiveness of cisplatin, a widely used chemotherapy drug for oral squamous cell carcinoma (OSCC), is often compromised by resistance, making it difficult to predict treatment outcomes.
Kah Young Lee +7 more
doaj +1 more source
ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway
Journal of Experimental & Clinical Cancer Research, 2018 Background ER-α36, a novel ER-α66 variant, has been demonstrated to promote tamoxifen resistance in breast cancer cells. However, the role and mechanisms of ER-α36 in cisplatin resistance of breast cancer cells remain unclear. This study investigates the
Linlin Zhu +6 more
doaj +1 more source
Acta Biochimica et Biophysica Sinica, 2023 Cisplatin resistance is a major obstacle in the treatment of non-small cell lung cancer (NSCLC). p32 and OPA1 are the key regulators of mitochondrial morphology and function. This study aims to investigate the role
Yu Chun-Xia +8 more
doaj +1 more source
HPV and CSC in HNSCC cisplatin resistance
Frontiers in Bioscience, 2015 Cisplatin (DNA intercalator), a standard chemotherapy drug often used to treat head and neck squamous cellular carcinoma (HNSCC) has very low response rates in recurrent disease of HNSCC, this is a major clinical problem today. However, a valuable window to look in to the underlying molecular aspects of a favorable and unfavorable cisplatin response is
Vishnu, Modur +2 more
openaire +2 more sources
Brazilian Journal of Medical and Biological Research, 2013 Cisplatin resistance remains one of the major obstacles when treating epithelial ovarian cancer. Because oxaliplatin and nedaplatin are effective against cisplatin-resistant ovarian cancer in clinical trials and signal transducer and activator of ...
W.J. Sheng +3 more
doaj +1 more source
Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma. [PDF]
PLoS ONE, 2014 Cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) reduces survival. In this study we hypothesized that methylation of key genes mediates cisplatin resistance.
Chi T Viet +5 more
doaj +1 more source
Scientific ReportsDrug resistance remains a critical challenge in cancer chemotherapy, particularly in oral squamous cell carcinoma (OSCC). Recent findings have highlighted the significant roles that autophagy and extracellular vesicles (EVs) play in contributing to ...
Kar-Yan Su +4 more
doaj +1 more source
LTBP2 regulates cisplatin resistance in GC cells via activation of the NF-κB2/BCL3 pathway
Genetics and Molecular BiologyGastric cancer (GC) often develops resistance to cisplatin treatment, but while latent transforming growth factor β-binding protein (LTBP2) is recognized as a potential regulator in GC, its specific role in cisplatin resistance is not fully understood ...
Jun Wang +4 more
doaj +1 more source
The contrasting activity of iodido versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes : control of cell selectivity, cross-resistance, p53 dependence, and apoptosis pathway [PDF]
, 2013 Organometallic half-sandwich complexes [M(p-cymene)(azo/imino-pyridine)X]+ where M = RuII or OsII and X ═ Cl or I, exhibit potent antiproliferative activity toward a range of cancer cells.
Sadler, P. J. +2 more
core +1 more source